So, you want to get better at Python? That’s cool. There are a ton of ways to learn, but honestly, just messing around with code and seeing how things work is a pretty solid approach. This article is ...

Beetroot juice, which is rich in nitrates, has been linked to changing the community of bacteria living in the mouth. Now, a new study has found that drinking this juice could reduce older adults’ ...

Even if you don’t know much about the inner workings of generative AI models, you probably know they need a lot of memory. Hence, it is currently almost impossible to buy a measly stick of RAM without ...

Let's be honest, we're all drama queens sometimes. Whether you're texting your bestie you're “literally dying” over the latest celebrity gossip or declaring on social media that Monday mornings are ...

Right now, many companies are worried about how to get more employees to use AI. After all, the promise of AI reducing the burden of some work—drafting routine documents, summarizing information, and ...

A new bill proposed by Democrats in the Virginia state legislature is raising concerns regarding the removal of minimum prison sentences for various violent felony crimes. Within days of Democratic ...

Need a better way to plan projects? Discover mind map examples that help you visually organize tasks, ideas, and strategies for clearer decision-making. Key takeaways: Mind maps show how visual ...

Household savings in China are markedly higher than in peer economies, which have been channeled into financing excessive investment. This paper examines the structural and cyclical factors ...

Send a note to Doug Wintemute, Kara Coleman Fields and our other editors. We read every email. By submitting this form, you agree to allow us to collect, store, and potentially publish your provided ...

Amazon Web Services (AWS) is bulking up its AI agent platform, Amazon Bedrock AgentCore, to make building and monitoring AI agents easier for enterprises. AWS announced multiple new AgentCore features ...

Skye Bioscience’s obesity candidate has failed to reduce weight in a phase 2 study, marking another setback for the CB1 inhibitor class. The biotech had been evaluating a 200-mg weekly subcutaneous ...